BLUE
$170.50
Bluebird Bio
BLUE
Earnings Whisper ®
N/A
1st Quarter March 2018
Consensus:  ($1.99)
Revenue:  $6.52 Mil
Wednesday
May 23
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BLUE reports earnings?
Beat
Meet
Miss

Where is BLUE's stock price going from here?
Up
Flat
Down
Stock chart of BLUE
Analysts
Summary of analysts' recommendations for BLUE
Score
Grade
Pivots
Resistance
$177.48
$175.17
$172.83

$170.52

Support
$168.18
$165.87
$163.53
Tweet
Growth
Description
Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.
Peers
BiogenAmgenGilead SciencesSeattle GeneticsNeurocrine BiosciencesBioCryst PharmaceuticalsNovavaxQiagen N.V.RepligenBio-Techne